Lupulone

Lupulone: A Comprehensive Reference

1. Identity and Chemical Characterization

Lupulone is a naturally occurring prenylated acylphloroglucinol belonging to the class of compounds collectively known as β-acids (beta-acids) of hops. Derived from the cones of the female hop plant, lupulone is a β-acid that contributes to the overall bitter flavor and aroma of beer along with α-acids. It is an organic chemical compound with the molecular formula C₂₆H₃₈O₄ and appears as a yellow powder. Its CAS Registry Number is 468-28-0.

The bitter acids of hops (Humulus lupulus L.) mainly consist of humulones or alpha-acids and lupulones or beta-acids. The beta-acids are structurally highly similar to the alpha-acids; they are the triprenylated analogues of the alpha-acids. The term "lupulone" is used to identify individual beta-acids; similar nomenclature as for the alpha-acids accounts for their varying acyl side chains.

Lupulone is specifically the analogue bearing an isobutyl side chain, and it is one of a set of three major β-acid congeners found in hop resin. The three analogues of the beta-acids are lupulone, ad-lupulone, and colupulone. Lupulone is one of four beta-acid analogues in hop resin, the others being adlupulone, colupulone, and prelupulone. Lupulone levels vary across hop varieties from roughly 30% to 55% of total beta acids; colupulone varies from roughly 20% to 55%, but adlupulone stays within a narrower range of 10% to 15%.

Beta-acids are the sum of their analogues, namely co-, n-, ad-, pre- and post-lupulone, with the last two being less common. The beta-acids cannot undergo isomerisation, as they lack a tertiary –OH group in the aromatic ring. The β-acid is less acidic and water-soluble than the isomerized α-acids.

Regarding biosynthesis, bitter acid biosynthesis in hops follows the pattern established for cannabinoid biosynthesis; in the case of hop bitter acids, the polyketide synthase responsible for the formation of the acylphloroglucinol core has been identified. This enzyme — phlorisovalerophenone synthase (valerophenone synthase, VPS) — utilized isovaleryl CoA or isobutyryl CoA as primers for polyketide formation.

1.1 Common Names and Synonyms

• Lupulone (IUPAC/trivial name)
• β-acid (hops); beta-acid
• Hop β-acid; lupulon (variant spelling)
• CAS 468-28-0

1.2 Natural Source and Botanical Context

Hop (Humulus lupulus L.) is a climbing dioecious plant belonging to the Cannabaceae family. This species is cultivated worldwide for its female inflorescences (cones), commonly called "hops," which are used in the brewing industry. Hop is a dioecious perennial vine that grows wild in the Northern hemisphere and is cultivated in temperate regions of Western Europe, the US Pacific Northwest (Washington and Oregon), and Asia.

Hop cones consist of a series of sets of four bracteoles and two bracts arranged about a central stalk or "strig," and develop from the inflorescence of the female plant. The lupulin glands — small, cup-shaped, resinous structures at the base of bracteoles — are the primary site of accumulation for bitter acids including lupulone. Hops produce infructescence (cones) from the female plant that contain less than 30% (dry weight) secondary metabolites such as the polyketides humulones (α-acids), lupulones (β-acids), and prenylated chalcones (e.g., xanthohumol).

A natural hops source can comprise from about 2% to about 12%, by weight of the hops source, of hops beta acids depending on the variety of hops. Beta acids are often present in hops up to 5–7%.

1.3 Common Forms and Preparations

Lupulone and related β-acids are encountered in several commercial forms. In brewing, whole hop cones, hop pellets, and concentrated hop extracts all deliver β-acids including lupulone. For research and potential biomedical applications, lupulone is isolated as a purified yellow crystalline or powder material. Beta acids are known to be highly unstable, being oxidized in the boiling wort to bitter hulupones and deteriorating in a matter of days or hours after crystallization; this lack of stability is overcome by conversion to hexahydrolupulone (hexahydro beta acids).

Losses of hop acids and essential oil begin as soon as hops are harvested, with the rate of loss depending on hop variety, hop form, storage conditions, and time of storage. The greatest decline is observed under aerobic conditions at 20 °C, where 64–88% of alpha-acids and 51–83% of beta-acids are lost. Anaerobic cold storage and pelletized forms provide improved stability. In nutraceutical and pharmaceutical research contexts, lupulone is sourced as isolated material or as enriched hops extracts; the use of lupulones as natural alternatives to antibiotics is increasing in the food industry and also in bioethanol production.

2. Traditional and Historical Use

Because lupulone is an intrinsic constituent of hop cones rather than an isolable traditional remedy per se, its historical use is inseparable from the traditional use of Humulus lupulus as a whole. Lupulone-containing hops were used for brewing, medicine, and food preservation across many cultures.

2.1 Early Cultivation and Brewing

Since lupulone is a component of hops, the history of the compound can be traced back to 736 AD in southern Germany, where hops plants were first cultivated. The commercial production of using lupulone in brewing was not until 1079 AD. Hop is best known for its use in beer brewing owing to its bittering flavor and floral aroma; today, the brewing industry uses as much as 98% of the produced hop crop worldwide.

Hildegard von Bingen noted as long ago as 1153 that the bitterness of hops prevents rot ("putredines prohibet in amaritudine sua"). The historic use of hops is interesting in that its technical properties — use as flavor and for the preservation of beer — were discovered in the Middle Ages, but reports of medicinal use from that time were not very encouraging. Hildegard von Bingen, the noted German abbess, herbalist, and author (1098–1179), wrote in Physica that hops had little use for humans.

2.2 Sedative and Nervine Use

Beyond its role in brewing, hop has long been employed in traditional medicine to relieve a variety of ailments, especially insomnia, excitability, and restlessness associated with nervous tension. Additionally, hop has been used to manage headaches and digestive complaints, making it a multifaceted remedy in folk medicine.

The use of hops as a mild sedative came from the observation of fatigue, tiredness, and sleepiness symptoms in hop pickers, apparently due to resin absorption during harvesting or processing hops. The tranquilizing and sleep-enhancing properties of H. lupulus were cited in old manuals of pharmacology and pharmacognosy dating to the late 19th and early 20th centuries, as well as in modern textbooks of phytotherapy. The German Commission E Monographs advised using the plant in the treatment of "discomforts during restlessness or anxiety and sleep disturbances."

Hops have long been used as a sedative and sleeping aid in drinks. In addition, soft pillows filled with hops have been popular. This practice was documented across Central and Northern Europe.

2.3 Cross-Cultural Traditional Uses

Between 1300 and 1600, there was a widespread use of hops as a remedy for fevers, spleen disorders, as a diuretic, and for liver purging. In North America, various indigenous tribes used hops as a remedy for various ailments. The Delaware used it for earache and toothache; the Cherokee used it against sleeping disorders; the Navajo against coughs and colds; and the Dakota used hop infusions as a cure for intestinal disorders and wound healing. Hops were also used in Ayurvedic medicine, a traditional medicine used in India since ancient times and still widespread in the subcontinent today.

Other examples of traditional uses include treatments against leprosy, toothache, fever, gastric problems, and anxiety, and use as a preservative, deodorant, and cattle fodder.

In digestive traditions, oleo-resins containing bitter substances (including lupulone) stimulate appetite, gastric secretion, and bile flow, thus improving digestion. The antimicrobial properties of hops were empirically understood long before their chemical explanation: there was, in the past, speculation that hops may have helped control brewhouse bacterial infections due to the presence of hop acids in the wort and beer.

3. Key Constituents, Chemical Context, and Active Compounds

Lupulone does not exist in isolation within hops; it is part of a broader chemical matrix. Hops are used traditionally in the brewing industry to confer bitterness, aroma, and flavor to beer; however, in recent years, it has been reported that female inflorescences contain a huge variety of bioactive compounds. Hop cones contain a wealth of bioactive compounds, including phenolics, procyanidins, flavonoids, and chalcones such as xanthohumol. Constituents include oleo-resins containing bitter substances (acylphloroglucides, humulone, lupulone, valerianic acid), volatile oil (humulene), tannins, estrogenic substance, flavonoids (kaempferol, quercetin, rutin), chalcones, and aspargin.

Within this matrix, the compounds sought by brewers are prenylated acylphloroglucinol derivatives, also called bitter acids, and in particular α-acids (humulone derivatives) which are isomerized into iso-α-acids during the brewing process; these compounds confer some bitterness and antiseptic properties to beer. The antimicrobial activity is mainly attributed to prenylated acylphloroglucinols, in particular to α-acids and β-acids (lupulone derivatives) and to prenylated chalcones, including xanthohumol.

4. Mechanisms of Action

4.1 Antimicrobial Mechanism

Lupulone's most extensively characterized mechanism of action is its antimicrobial activity against Gram-positive bacteria. The hop acids act as ionophores against Gram-positive bacteria, inhibiting their growth. This activity results from the hydrophobic interactions of prenyl groups present in α- and β-acid structure with the bacterial cell walls.

More specifically, early research in Bacillus subtilis reported that hop constituents, including lupulone, induced primary membrane leakage and subsequent inhibition of several cellular functions, suggesting that the bacterial plasma membrane is the primary target. Research on Lactobacillus brevis, a common beer spoilage bacterium, found that the activity of hop acids is strongly enhanced at low pH, indicating that the undissociated form is mainly responsible for the antibacterial action. Additionally, hop acids were found to act as ionophores that transport H⁺ across the bacterial plasma membrane, thereby altering ion gradients and lowering intracellular pH. The proton ionophore action was later confirmed using bilayer lipid membrane measurements.

The hops plant produces a range of bioactive secondary metabolites, including antimicrobial prenylated phloroglucinols, which are commonly called alpha- and beta-acids. These latter compounds can be considered phyto-ionophores, phytochemicals with a similar antimicrobial mechanism of action to ionophore antibiotics (e.g., monensin, lasalocid). Like ionophores, the hop beta-acids inhibit rumen bacteria possessing a classical Gram-positive cell envelope.

When the mechanism of action and spectrum of activity against rumen bacteria are considered, lupulone and related compounds distinctly resemble feed ionophores. These hop compounds could be thought of as "phyto-ionophores" for biological points of comparison. In particular, lupulone inhibits the activity of Gram-positive bacteria S. bovis, which are one of the main producers of lactate. However, some Gram-positive bacteria are not sensitive to lupulone, such as bacteria of the class Negativicutes.

4.2 Anticancer Mechanisms

Multiple in vitro studies have identified apoptosis induction as a key anticancer mechanism. Research aimed to compare death signalling pathways triggered by lupulone in TRAIL-sensitive human colon cancer cells (SW480) and in their derived TRAIL-resistant metastatic cells (SW620); lupulone (40 µg/ml) up-regulated expression of TRAIL DR4/DR5 death receptors at the cell surface of both cell lines, even in the absence of exogenous TRAIL ligand.

In SW480 cells, lupulone triggered cell death through a cross-talk between TRAIL-DR4/DR5 and the mitochondrial (intrinsic) pathways involving caspase-8 activation and Bid protein cleavage. As a consequence, mitochondrial cytochrome c was released into the cytosol and activation of caspases-9 and -3 was observed. In the metastatic SW620 cells, lupulone restored the sensibility of these cells to TRAIL ligand and activated the extrinsic apoptotic pathway via DR4/DR5 death receptors and the involvement of the caspase-8/caspase-3 cascade.

In prostate cancer cells, the anticancer effect of lupulone derivatives is associated with induction of apoptosis and autophagy, as determined by increases of DNA fragmentation and LC3I/LC3II conversion respectively. Inhibition of apoptosis using a pan-caspase inhibitor resulted in increased levels of autophagy. Atg4β expression was increased in prostate cancer cells after treatment with lupulone; transfection of cells with siRNA against Atg4β resulted in increased levels of apoptosis. Treatment of prostate cancer cells with lupulone derivatives initiated two modes of cell death: apoptosis as a killing pathway and autophagy as a protection against cell death.

4.3 Antiangiogenic Mechanism

Lupulone has been shown to possess antiangiogenic properties in both cell-based and animal models. Lupulone (2.5–50 µg/ml) induced a concentration-dependent inhibition of HUVEC (human umbilical vein endothelial cell) proliferation and chemotaxis. Lupulone caused a significant reduction of closed capillary-like structures in Matrigel, indicating a strong inhibitory effect on neovascularization. In mice receiving lupulone (20 mg/kg/day) in drinking water for 21 days, new vessel formation was reduced by 50% in matrigel plugs implanted under the skin when compared with controls.

4.4 Anti-inflammatory Mechanisms

In dermatology, hop extracts are used due to their anti-inflammatory, antibacterial, and photoprotective properties. Compounds such as humulones and lupulones exhibit activity against bacteria responsible for acne and skin infections, while simultaneously limiting inflammatory responses induced by UV radiation. Studies in keratinocytes confirm the ability of hop extracts to inhibit interleukin-6 production, which further supports their potential in skin care and protection.

5. Scientific Evidence by Area of Use

5.1 Antimicrobial Activity

Evidence level: In vitro and animal studies; no published human clinical trials specifically for lupulone as an isolated antimicrobial agent.

Lupulones, hops β-acids, are one of the main constituents of the hops resin and have an important contribution to the overall bacteriostatic activity of hops during beer brewing. The antibacterial spectrum of lupulone is largely restricted to Gram-positive organisms. In vitro studies have shown lupulone to repress the growth of bacteria that cause skin infection such as Propionibacterium acnes, Staphylococcus epidermidis, and Staphylococcus aureus.

A 2019 study published in Molecules tested a hop extract rich in humulones and lupulones for its antioxidant and anti-inflammatory effects in human primary keratinocytes (HPKs) and analyzed its antibacterial properties; antimicrobial activities were found against both P. acnes and S. aureus (including MRSA), and the gel formulation containing hop extract showed antibacterial activity superior to that of the placebo gel. This study used an extract enriched in both α- and β-acids, rather than isolated lupulone, limiting the ability to attribute effects to lupulone alone.

Activity-guided fractionation research published in 2023 directly identified lupulone as a key contributor: activity-guided fractionation detected the strongest effect for lupulone and adlupulone in hop extract antibacterial activity. Xanthohumol and lupulones, prevalent hop active compounds, inhibit C. acnes, S. epidermidis, S. aureus, and Streptococcus pyogenes growth.

In ruminant nutrition science, the antimicrobial effects of lupulone against rumen Gram-positive bacteria have been studied in animal models and in vitro, showing that lupulone functions in a manner similar to ionophore antibiotics. Hops β-acid, purportedly lupulone, also inhibits important Gram-positive pathogens such as C. perfringens.

Importantly, lupulones are very reactive towards the 1-hydroxyethyl radical and are very oxidizable. Oxidation causes decomposition resulting in loss of the lupulone antimicrobial activity. This instability is a significant practical challenge for therapeutic applications.

Limitations: All antimicrobial evidence is from in vitro or animal studies. No randomized clinical trials in humans have been published evaluating lupulone as a standalone antimicrobial agent.

5.2 Cancer Chemoprevention and Anticancer Activity

Evidence level: In vitro cell studies and animal models; no human clinical trials.

The most detailed published study on lupulone's anticancer properties addressed colorectal cancer. A 2007 study published in Carcinogenesis by Roussi et al. used both a human metastatic cell line and a rat model: the study evaluated the antiproliferative mechanisms of lupulones on a human metastatic colon carcinoma-derived cell line (SW620 cells) and assessed chemopreventive effects in a model of colon carcinogenesis. SW620 cell growth was inhibited by 70% after a 48-hour exposure to lupulones (40 µg/ml). Lupulones up-regulated expression of Fas receptor (Fas) and Fas ligand (FasL) as well as TRAIL-R1 (DR4) and -R2 (DR5) receptor proteins, suggesting the involvement of Fas and TRAIL receptor-mediated pathways in lupulone-induced apoptosis. Lupulones also increased the mitochondrial membrane permeability.

In the animal component of the same study, colon carcinogenesis was initiated in Wistar rats by intraperitoneal injections of azoxymethane (AOM), once a week for 2 weeks. One week after the last injection, rats received lupulones (0.001% or 0.005%) in drinking water. After 7 months of treatment, the colons of rats receiving 0.001% and 0.005% lupulones showed, respectively, a 30% and a 50% reduction (P < 0.05) of the number of preneoplastic lesions (aberrant crypt foci). In addition, a drastic reduction (70–80%) of the total number of tumors in the colon of rats treated with lupulones was observed when compared with the AOM control group. Lupulones induced apoptosis in SW620 colon-derived metastatic cells by activating both Fas and TRAIL death receptor signaling pathways, and antagonize at a low dose (4 mg/kg/day) colon cancer development.

A 2008 follow-up study published in Apoptosis compared apoptotic pathways in TRAIL-sensitive (SW480) and TRAIL-resistant (SW620) colon cancer cells. The demonstration that lupulone is able to activate TRAIL-death signalling pathways even in TRAIL-resistant cancer cells highlights the potential of this natural compound for cancer prevention and therapy.

For prostate cancer, a study investigated the functional role of different modes of cell death mediating the anticancer effect of lupulone derivatives in prostate cancer cells. Lupulone, a β-acid derived from hop extracts, had been shown to exhibit cytotoxic activity against cancer cells.

Regarding antiangiogenic effects, a PubMed-indexed 2008 study reported: the data demonstrate that lupulone is able to inhibit angiogenesis in vitro and in vivo. Lupulone emerges as a potential chemopreventive agent considering its strong antiangiogenic properties.

Limitations: All cancer-related evidence is limited to cell culture (in vitro) and rodent (in vivo) models. The concentrations used in cell studies (e.g., 40 µg/ml) may not be achievable in human tissues following oral administration. No human clinical trials or Phase I/II studies using lupulone for cancer prevention or treatment have been published in peer-reviewed literature.

5.3 Dermatological Applications

Evidence level: In vitro cell studies; one published extract-based human keratinocyte study.

Lupulone is a compound extracted from the flowers of Humulus lupulus (hops) that exhibits moderate to strong anticollagenase inhibitory activities and bactericidal activity against P. acnes, with a minimum inhibitory concentration (MIC) of 0.1 µg/mL.

A hop extract enriched in humulones and lupulones was tested in a laboratory study using human primary keratinocytes. The extract was tested for its antioxidant and anti-inflammatory effects in human primary keratinocytes (HPKs) and for its antibacterial properties. Antimicrobial activities were found against both P. acnes and S. aureus (including MRSA), and the gel formulation containing the hop extract showed antibacterial activity superior to that of the placebo gel.

Xanthohumol and bitter acids (α-bitter acids like humulone and β-bitter acids like lupulone) from hop (Humulus lupulus L.) show antibacterial effects against P. acnes.

Limitations: Studies on dermatological applications have used mixed extracts containing multiple bioactive compounds, not isolated lupulone. The relative contribution of lupulone versus other hop acids or xanthohumol cannot be precisely assigned from these studies. No randomized clinical trials in acne or skin conditions using lupulone alone have been published.

5.4 Sedative and Sleep-Related Uses (Hops Context)

Evidence level: Clinical evidence exists for hops preparations, but not for isolated lupulone.

It is important to note that the well-documented sedative effects of hops are attributed primarily to 2-methyl-3-buten-2-ol (a degradation product of humulone), the phloroglucinol 8-prenylnaringenin, and essential oil constituents rather than to lupulone specifically. In traditional medicine, the dried flowers were recommended for the treatment of sleep disturbances, restlessness, mania, toothache, and earache. Laboratory tests have shown that components of hop extract bind with melatonin receptors. Further research is investigating which ingredients are responsible for this phenomenon. Melatonin is also known as the sleep hormone and controls the sleep-waking time rhythm; this could be the reason why hops help induce sleep. Hops (often in combination with valerian) are mainly used as a herbal sleep aid to combat difficulties in falling asleep.

Limitations: No published clinical evidence specifically implicates lupulone in sedative or sleep-promoting effects in humans. The mechanistic and clinical evidence for sedation applies to the whole hop extract or specific other phytochemicals therein.

5.5 Antioxidant Activity

Evidence level: In vitro and animal studies only.

Lupulones are easily oxidizable and have been shown to be very reactive toward the 1-hydroxyethyl radical, with apparent bimolecular rate constants close to diffusion control. This radical-scavenging reactivity underlies the antioxidant properties attributed to lupulone. Lupulone is a beta-acid from the hop plant H. lupulus with diverse biological activities including antibacterial, antioxidant, and anticarcinogenic properties.

A significant challenge in the application of hop compounds remains their limited bioavailability. Despite relatively good intestinal absorption, systemic bioavailability remains limited; however, modern delivery systems significantly increase the stability and plasma concentrations of these compounds.

5.6 Ruminant Nutrition and Antimicrobial Growth Promotion

Evidence level: In vitro and animal (ruminant) studies.

A body of preclinical research has investigated lupulone as an alternative to antibiotic growth promoters in livestock. The study presents characteristics of biologically active substances of hop cones. Hop cones contain biologically active components similar to ionophore antibiotics by action — specifically the prenylated flavonoids humulone (α-acid), lupulone (β-acid) and their derivatives. These components of hop cones can be regarded as a potential substitute for ionophoric antibiotics. In particular, lupulone and some other components of hop cones inhibit the activity of Gram-positive bacteria, causing reactions similar to ionophore antibiotics.

Under the action of biologically active acids of hop cones in the rumen, the production of lactic acid decreases. Reducing ruminal lactic acid production is the primary metabolic benefit attributed to ionophore-type growth promoters in cattle, suggesting a practical veterinary application.

6. Body Systems and Health Areas Associated with Lupulone

• Gastrointestinal system: Chemopreventive activity in colorectal cancer (preclinical); traditional use as digestive bitter to stimulate secretion.
• Immune/antimicrobial: Gram-positive antibacterial action via a proton ionophore mechanism; active against S. aureus (including MRSA), P. acnes, S. epidermidis, C. perfringens, S. bovis.
• Oncology (preclinical): Antiproliferative and pro-apoptotic activity in colon and prostate cancer cell lines; antiangiogenic activity in vitro and in rodents.
• Skin/dermatology: Anti-inflammatory and antibacterial effects in keratinocytes; activity against acne-associated pathogens.
• Cardiovascular/angiogenesis: Inhibition of endothelial cell proliferation and new vessel formation (preclinical models only).
• Nervous system (hops extract context, not lupulone-specific): Traditional and pharmacological sedative/sleep use is attributed to the broader hops extract, not to isolated lupulone.

7. Dosages Reported in Research Studies

No established human dosage for isolated lupulone exists. The following dosages are reported in published preclinical studies only:

• In vitro colon cancer (SW620 cells): SW620 cell growth was inhibited by 70% after a 48-hour exposure to lupulones at 40 µg/ml.
• In vitro antiangiogenic (HUVEC cells): Lupulone (2.5–50 µg/ml) induced a concentration-dependent inhibition of HUVEC proliferation and chemotaxis.
• Rat colon carcinogenesis model: Rats received lupulones at 0.001% or 0.005% in drinking water for 7 months following azoxymethane initiation. This corresponds to approximately 4 mg/kg/day (low dose) for colon cancer development antagonism.
• Mouse antiangiogenic (matrigel plug) model: Mice received lupulone at 20 mg/kg/day in drinking water for 21 days, resulting in a 50% reduction of new vessel formation.
• Antimicrobial (P. acnes): Lupulone exhibits bactericidal activity against P. acnes, with a minimum inhibitory concentration (MIC) of 0.1 µg/mL.
• Antimicrobial (S. aureus): Lupulone has shown strong antibacterial activity, particularly against Gram-positive bacteria such as Staphylococcus aureus, with MIC values as low as 1–4 µg/mL, by disrupting membrane integrity.

No human pharmacokinetic or dose-finding studies for isolated lupulone were identified in the published literature. A significant challenge in the application of hop compounds remains their limited bioavailability.

8. Safety Considerations

8.1 Chemical Instability

Beta acids are known to be highly unstable, being oxidized in the boiling wort to bitter hulupones and by themselves deteriorating in a matter of days or hours after crystallization. Lupulones are very reactive towards the 1-hydroxyethyl radical and are very oxidizable. Oxidation causes decomposition resulting in loss of the lupulone antimicrobial activity. This instability substantially limits the compound's practical utility in preparations intended for biomedical use and represents a formulation challenge.

8.2 Occupational Exposure and Skin Sensitization

In a survey of Humulus lupulus farmers, exposure to hops was reported to cause the greatest number of skin problems; 14 of 73 (19.2%) of the farmers reported work-related skin symptoms, 11% of which were caused by hops. In hops pickers, dermatitis has been attributed to mechanical abrasion by the rough hairs on the climbing stem. It has also been suggested that lupulin, the yellow powdery secretion of the glandular hairs on the scales of the strobiles, may be responsible for the irritation. These findings relate to occupational whole-plant exposure, not to oral ingestion of isolated lupulone.

8.3 Derivative Safety Data (Hexahydrolupulone)

Patent literature on the hydrogenated derivative notes: as a derivative of a generally-recognized-as-safe hop extract, hexahydrolupulone can be considered negligibly toxic when ingested. This statement applies to the reduced derivative and is from a patent document, not a formal toxicological study.

8.4 Bioavailability and Systemic Exposure

A significant challenge in the application of hop compounds remains their limited bioavailability. Despite relatively good intestinal absorption, systemic bioavailability remains limited; however, modern delivery systems significantly increase the stability and plasma concentrations of these compounds. The practical significance of this for human health effects of lupulone specifically has not been formally quantified in published clinical studies.

8.5 Selectivity and Gram-Negative Resistance

Some Gram-positive bacteria are not sensitive to lupulone, such as bacteria of the class Negativicutes. Gram-negative bacteria are inherently resistant due to the protective outer membrane, which prevents lupulone's hydrophobic prenyl chains from reaching the inner membrane. Despite the strong antimicrobial activity of hop beta-acids, the underlying mechanisms of their activity are not yet fully understood.

8.6 Human Clinical Data Gap

There are currently no published Phase I, II, or III clinical trials evaluating the safety, tolerability, pharmacokinetics, or efficacy of isolated lupulone in human subjects. All biomedical research published to date consists of in vitro cell culture studies and rodent animal models. Existing observations have led researchers to suggest the use of lupulones for colon cancer chemoprevention trials, but such trials have not yet been published. The absence of human pharmacokinetic data means that safe and effective human dosing cannot be established from current evidence.

References

• Šilarová P et al. "On the reaction of lupulones, hops β-acids, with 1-hydroxyethyl radical." Free Radical Biology and Medicine, 2012. PubMed PMID: 23031058
• Wikipedia. "Lupulone." Accessed 2025.
• Roussi S et al. "Chemopreventive effects of lupulone, a hop β-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis." Carcinogenesis, 2007. PubMed PMID: 17434926
• Roussi S et al. "Chemopreventive effects of lupulone..." Carcinogenesis 28(7):1575–1581, 2007. Oxford Academic.
• Lamy V et al. "Lupulone, a hop bitter acid, activates different death pathways involving apoptotic TRAIL-receptors, in human colon tumor cells and in their derived metastatic cells." Apoptosis, 2008. PubMed PMID: 18726190
• "Antiangiogenic properties of lupulone, a bitter acid of hop cones." PubMed PMID: 18383859
• Flythe MD et al. "Hops (Humulus lupulus L.) Bitter Acids: Modulation of Rumen Fermentation and Potential as an Alternative Growth Promoter." Frontiers in Veterinary Science, 2017. PubMed PMID: 28871284
• Flythe MD et al. "Hops (Humulus lupulus L.) Bitter Acids: Modulation of Rumen Fermentation..." Frontiers in Veterinary Science, 2017. Full text.
• Bocquet L et al. "Phenolic Compounds from Humulus lupulus as Natural Antimicrobial Products: New Weapons in the Fight against Methicillin Resistant Staphylococcus aureus, Leishmania mexicana and Trypanosoma brucei Strains." PMC, 2019. PMC6472001
• Almaguer C et al. "Humulus lupulus L. as a Natural Source of Functional Biomolecules." Applied Sciences 10(15):5074, 2020. MDPI.
• ScienceDirect Topics. "Lupulone – an overview."
• ScienceDirect Topics. "Lupulon – an overview." Pharmacology/Toxicology.
• Pawlaczyk-Graja I et al. "Biological Activity of Hops (Humulus lupulus L.): Molecular Mechanisms and Significance for Human Health—A Review." Nutrients 18(7):1056, 2026. MDPI.
• Wölfle U et al. "Hop Extract Acts as an Antioxidant with Antimicrobial Effects against Propionibacterium Acnes and Staphylococcus Aureus." Molecules 24(2):223, 2019. MDPI.
• "An Updated Review of the Genus Humulus: A Valuable Source of Bioactive Compounds for Health and Disease Prevention." PMC, 2022. PMC9782902
• Verheyen J et al. "Cell Envelope Modifications Generating Resistance to Hop Beta Acids and Collateral Sensitivity to Cationic Antimicrobials in Listeria monocytogenes." Microorganisms 11(8):2024, 2023. MDPI.
• "Identification of colupulone and lupulone as the main contributors to the antibacterial activity of hop extracts using activity-guided fractionation and metabolome analysis." Food Research International, 2023. ScienceDirect.
• "The Stability of Hop (Humulus lupulus L.) Resins during Long-Period Storage." PMC, 2023. PMC9960943
• Patzak J et al. "Hop (Humulus lupulus L.): Traditional and Present Use, and Future Potential." Economic Botany, 2021. Springer.
• "Humulus lupulus L.: Pharmacological Properties and Medicinal Use." Springer Nature Link, 2025.
• Cosmetic Ingredient Review. "Safety Assessment of Humulus lupulus (Hops)-Derived Ingredients." CIR, 2016.
• Koetter U, Biendl M. "Humulus lupulus: A Review of its Historic and Medicinal Uses." HerbalGram, 2010. Hopsteiner.
• "Ionophore antibiotics and hop cones as regulators of digestion and metabolism in ruminants." ResearchGate, 2024.